Who makes Treatment 360 days DAPT?

Treatment 360 days DAPT is developed by Diagram B.V..

What development phase is Treatment 360 days DAPT in?

Treatment 360 days DAPT is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Treatment 360 days DAPT

Diagram B.V. · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Treatment 360 days DAPT
Also known as	Subjects will be treated with Aspirin and P2Y12 inhibitor. Prasugrel (10, mg/day) or Ticagrelor (180 mg/day) are strongly recommended as compared, to Clopidogrel (75 mg/day))., Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up, to 360 days, after which patients will continue on monotherapy with ASA
Sponsor	Diagram B.V.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment 360 days DAPT CI brief — competitive landscape report
Treatment 360 days DAPT updates RSS · CI watch RSS
Diagram B.V. portfolio CI